Watching ESSA Pharma; Zacks Small-Cap Research Sets $27 Price Valuation; Says This Model Is Highly Dependent Upon Continued Clinical Success Of EPI-7386/TPD And Will Be Adjusted Accordingly Based Upon Future Clinical Results
Portfolio Pulse from Happy Mohamed
Zacks Small-Cap Research has set a $27 price valuation for ESSA Pharma (EPIX), stating that the valuation is highly dependent on the continued clinical success of EPI-7386/TPD and will be adjusted based on future clinical results.
May 18, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ESSA Pharma's stock price may be influenced by Zacks Small-Cap Research's $27 price valuation, which is dependent on the continued clinical success of EPI-7386/TPD.
Zacks Small-Cap Research's price valuation of $27 for ESSA Pharma is based on the continued clinical success of EPI-7386/TPD. If the clinical trials show positive results, it could lead to an increase in EPIX's stock price. However, if the trials fail to meet expectations, the valuation may be adjusted, potentially impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100